It is important to control or prevent protein glycosylation because it induces diabetes and related complications. Peptidomimetics show great therapeutic prospects in this respect. Based on this, CD BioSciences provides global customers with a wide range of peptidomimetic development services with anti-glycosylation activity, and assists in basic research and drug development related to protein glycosylation.
Overview of Glycosylation
Protein glycation refers to the reversible reaction of amino groups in proteins, peptides and lipids with reducing sugars, and occurs through a series of complex sequential reactions, including the formation of Schiff bases, Amadori products, and finally the formation of advanced glycation end products. In the presence of generally high glucose levels, molecular rearrangements of glycosylation products lead to irreversible formation of advanced glycation end-products (AGEs). AGEs mainly activate a variety of signaling mechanisms through the AGEs receptor (RAGE) to cause cellular stress, cause cellular dysfunction, and damage target organs, thereby causing diseases such as diabetes (DM), atherosclerosis, and neurodegenerative diseases and related complications.
Fig. 1 Pictorial representation of glycation. (Chilukuri, et al., 2018)
Strategies for Inhibiting AGEs
To combat the formation and accumulation of AGEs, we need to consider reducing the levels of ages in vivo from different perspectives, and peptides can be used as drug molecules of these different therapeutic strategies for targeted treatment. Natural carnosine, which currently exists in many organisms in muscle and nerve tissue, has been shown to have anti-glycosylation activity. Although it may involve a variety of mechanisms, it was found that carnosine can inhibit the formation of AGE by quenching active carbonyl substances. However, natural active peptides are often limited by their own structure, showing the disadvantages of poor stability and low targeting.
Therefore, the development of peptidomimetics based on the structure or function of natural peptides has a better market prospect, and these peptidomimetics often show better plasma stability and bioavailability.
Fig. 2 Strategies to inhibit AGE formation.
Peptidomimetics for the Treatment of Diabetes
Biological therapy for diabetes patients usually focuses on injection of various insulin products. Developing an oral insulin administration route will be a great benefit for diabetes patients, not only because it is convenient, but also because oral treatment will reduce the side effects of insulin administration, such as weight gain and hypoglycemia. However, for oral administration, peptide ligands must reach their targets before they can be effectively diagnosed or treated. The development of peptidomimetics can fully solve this technical bottleneck and serve as a potential lead compound for oral drugs for the treatment of diabetes.
Our Services
CD BioSciences provides comprehensive peptidomimetic development services with anti-glycosylation activity.
- Using our advanced PepDomTM platform to focus on the whole process of AGEs formation, accumulation and action, and look for developable target peptidomimetics to prevent the damage of glycosylation to the body.
- We provide the development of peptidomimetics that regulate glycosylation-related pathways that may not directly participate in or inhibit the glycosylation process, including the following:
- Regulation of glycosylation-related hormones secretion and synthesis
- Regulation of glycosylation-related nutrient metabolic pathways
- Regulation of glycosylation-related oxidative defense processes
- Regulation of glycosylation-related protein-protein interactions
- Regulation of immune-related pathways during glycosylation
- Regulation of other related pathways during glycosylation
- We also provide a series of peptidomimetic development services for the treatment of diabetes. Our unique technology will have the potential to become the leading technology for the development of oral diabetes drugs.
Advantages of Our Peptidomimetics
|
High biological activity against target |
|
Extensive therapeutic effects
|
|
Low level of cytotoxicity
|
|
Absence or low levels of accumulation in body tissues
|
CD BioSciences focuses on developing peptidomimetics with anti-glycation. As long as you provide the goals you are interested in, our professional team will solve them immediately. Welcome to contact us for the best solution.
Reference
- Chilukuri, H., Kulkarni, M. J., & Fernandes, M. (2018). Revisiting amino acids and peptides as anti-glycation agents. MedChemComm, 9(4), 614–624.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
